Clinical, Etiological and Imaging Profile of Posterior Reversible Encephalopathy Syndrome: A Prospective and Follow-Up Study

Saurabh Bansal, Ramandeep Bansal, Manoj Kumar Goyal, Aastha Takkar, Ramandeep Singh, Paramjeet Singh, Vivek Lal

Departments of Neurology, Obstetrics and Gynecology, Ophthalmology and Radio-Diagnosis and Intervention Radiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Abstract

Background: Although first described more than two decades ago, posterior reversible encephalopathy syndrome (PRES) continues to be enigmatic. We prospectively followed consecutive patients of PRES both clinically and radiologically for a better understanding of natural history, symptomatology, and prognosis of this not so uncommon entity. Patients and Methods: The current study included 22 consecutive patients of PRES who were followed both clinically as well as radiologically at a tertiary care institute in Northern India from December 2014 to June 2016. Results: Mean age was 30.68 ± 12.68 years. The most common symptoms included altered sensorium (77.3%), headache (72.7%), seizures (63.6%), vomiting (36.4%), and visual disturbances (22.7%). About 94.5% of patients had parieto-occipital signal changes on neuroimaging. Magnetic resonance imaging (MRI) (n = 20) revealed involvement of sites considered atypical for PRES in 95% (frontal [55%], temporal [40%], cerebellum [40%], basal ganglia [15%], deep white matter [10%] and brainstem [10%]). Diffusion restriction, haemorrhage, and contrast enhancement were seen in 30%, 22.2%, and 25% of patients. At 3 months follow-up, modified Rankin scale was 0 in 19 patients and 1 in 1 patient. Two (9.1%) patients died. Eight (36.4%) patients had eclampsia, 5 (22.7%) each had chronic kidney disease and essential hypertension whereas 2 (9.1%) each had immune-mediated disorders and drug-induced PRES. None of the clinical or imaging features predicted outcome in PRES. Conclusion: Atypical MRI presentations of PRES are common, and there is a need to keep a strong index of suspicion for the diagnosis of PRES. The prognosis of PRES is good, and most cases show excellent recovery, particularly if underlying etiology can be treated satisfactorily.

Keywords: Eclampsia, hypertension, posterior reversible encephalopathy, posterior reversible encephalopathy syndrome

Introduction

Ever since its first description by Hinchey et al. in 1996, many cases of posterior reversible encephalopathy syndrome (PRES) have been reported worldwide. Diagnosis of PRES is based on a constellation of clinical and radiological findings, the common clinical symptoms being altered consciousness, seizures, headaches as well as visual disturbances, and common radiological findings being reversible signal changes in the subcortical white matter areas of the brain. The common radiological changes on noncontrast computed tomography (CT) scan of brain include hypodense lesions in areas supplied by posterior cerebral circulation while magnetic resonance imaging (MRI) of brain often reveals areas of vasogenic edema as hypointense areas on the T1-weighted MR images and hyperintense areas on the T2-weighted/fluid-attenuated inversion recovery (FLAIR) MR sequences, with lack of diffusion restriction.

In spite of unique clinical presentation and a characteristic radiology, the uncommon occurrence and varied presentation of PRES can result in diagnostic difficulties resulting in unnecessary diagnostic and therapeutic interventions. Furthermore with increasing use of MRI in neurology, more and more atypical presentations of PRES are being recognized, knowledge of which is essential to correct diagnosis appropriate management. Furthermore, natural history of PRES has not been delineated in detail. Although conventionally thought to be reversible, recent studies have suggested that this may not always be true with a reported mortality rate of 15% and a significant risk of subsequent neurological impairment.

Despite a well known entity for the past two decades, much of the information regarding PRES has come from poorly conducted prospective studies or retrospective data. In addition, there is remarkable lack of studies from Indian subcontinent. Thus, we planned to carry out this study for better understanding of prevalence, natural history, and prognosis of this not so uncommon disease entity.

Aim and objectives

1. To study etiological, clinical, and radiological profile as well as outcome of PRES in North Indian population

Address for correspondence: Dr. Vivek Lal, Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. E-mail: vivekl44@yahoo.com

Submitted: 30-Aug-2018 Revised: 03-Sep-2018 Accepted: 21-Sep-2018 Published: 25-Feb-2020

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

DOI: 10.4103/aian.AIAN_379_18
2. To evaluate association of various clinical and radiological parameters with final outcome in PRES.

Patients and Methods

The current prospective longitudinal observational study was conducted at a tertiary care institute in Northern India from December 2014 to June 2016. During this period, we identified 22 consecutive patients with PRES who were included in the study. As we planned at least 3 month follow-up for each patient, recruitment of patients was limited to the first 15 months of the study period. The study was improved by Institutional Ethics Committee and written informed consent was obtained from all the patients before inclusion in the study. The inclusion criteria for the study are listed below:

1. Age >14 years
2. Variable combination of clinical manifestations suggestive of PRES: seizure activity, consciousness impairment, headaches, visual abnormalities, nausea/vomiting, and focal neurological signs
3. Brain imaging consistent with diagnosis of PRES: Two neuro physicians and an experienced neuroradiologist should have a consensus that MRI signal abnormalities are consistent with PRES
4. Clinical or radiological proof of reversibility (at least partial)
5. Patients willing to give written informed consent.

Once enrolled, detailed history was obtained and thorough general physical, systemic and neurological examination was carried out. All the relevant clinical and radiological data were noted on a predesigned pro forma. Hypertension was diagnosed on the basis of Joint National Committee 8 criteria. All the patients underwent detailed laboratory testing, MRI brain as well as ophthalmological testing by a trained ophthalmologist. Visual evoked potentials (VEPs), fundus examination, visual field charting, electroencephalography (EEG), and cerebrospinal fluid (CSF) analysis were carried out whenever deemed necessary. Modified Rankin scale (MRS) scoring was used as an outcome measure for the degree of disability or dependence both at presentation and at 3 months follow-up.

Imaging studies were reviewed by an experienced neuroradiologist, and discrepancies were reviewed to come to a consensus. All patients underwent MRI imaging with T2 weighted, T2 FLAIR, T1-weighted, and diffusion-weighted imaging sequences. Additional sequences like contrast-enhanced T1-weighted and time-of-flight intracranial MR angiography, were done whenever deemed necessary.

A diagnosis of PRES was considered whenever typical imaging findings were seen as described by Bartynski and Boardmann:11

1. Dominant parieto-occipital (PO) pattern
2. Holohemispheric watershed pattern
3. Dominant superior frontal sulcus pattern
4. Asymmetrical or partial expression (A/P) of the three primary patterns.

The imaging findings were also described according to their site, i.e., frontal, parietal, occipital, temporal, deep white matter, basal ganglia/thalami, brainstem, and cerebellum as well imaging characteristics.

Statistical analysis

Data were analyzed using IBM-Statistical Package for the Social Sciences, version 22 (Armonk, New York, IBM corp) and Microsoft excel build 14.07200.5000 32bit ©2010 Microsoft corporation. Continuous parametric variables, for example, age, blood pressure, pulse rate, complete biochemistry, complete hemogram, clinical symptoms with duration, etc., were analyzed by applying analysis of variance test, whereas skewed variables were analyzed using Mann–Whitney U test/Kruskal–Wallis H test.

Data were expressed in frequency, percentage, mean, median and standard deviation (SD) as per variability of data. Two-tailed P ≤ 0.05 was considered statistically significant with 95% confidence interval.

Results

Demographic features

Mean (± SD) age was 30.68 ± 12.68 years (range 15–68 years). Maximum patients (n = 9, 40.90%) were in the 3rd decade of age followed by five (22.72%) in the 4th decade. Thus, PRES is a disorder of young adults. Females (n = 17, 72.3%) dominated the study group.

Clinical features

In the current study, the most common presentation was encephalopathy (n = 17; 77.3%), followed by headache (n = 16; 72.7% [holocranial-10; occipitocervical-5; left hemicranial-1]), seizures (n = 14; 63.6% [generalized tonic-clonic in all; mean 1.428 seizures per person]), vomiting (36.4%), visual disturbances (n = 5; 22.7% [2-no perception of light; 3-blurring of vision with visual acuity more than 3/60]), hemiparesis (5.6%), facial palsy (5.6%), and dizziness (5.6%). Headache persisted for >2 weeks among 6 (27.3%) individuals. Two patients died during the study. At 3 months follow up (n = 20), all individuals were free from headache. All individuals with seizures received antiepileptic drugs and were seizure free without any recurrence at 3 months follow-up. Patients with absent light perception received five doses of intravenous methyl prednisolone (1 g daily) and recovered completely during the hospital stay. Remaining patients improved spontaneously with meticulous control of blood pressure. Hypertension was noted in 20 (90.9%)
patients. Mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) pressures were 173.09 mmHg and 99.18 mmHg whereas peak SBP and DBP were 250 mmHg and 134 mmHg, respectively. Six (27.3%) patients [patient number 6, 7, 13, 17, 19, 20 in Tables 1 and 2] needed mechanical ventilation. These results are summarized in Table 1.

**Radiological features**
Twenty-one (94.45%) patients had CT/MRI changes in the PO regions similar to the changes which are classically stated in the literature. The MRI findings (n = 20) are summarized in Table 2. The most striking feature noted in our study group was the predominance of involvement of atypical sites on MRI (n = 19; 95%), i.e., involvement of areas beyond the classically described posterior circulation territory. Atypical sites of signal changes included frontal (n = 11; 55%), temporal (n = 8; 40%), cerebellum (n = 8; 40%), basal ganglia (n = 3; 15%), deep white matter (n = 2; 10%), and brainstem (n = 2; 10%) [Figures 1 and 2].

**Hemorrhage in posterior reversible encephalopathy syndrome**
Five (22.72%) patients had hemorrhagic PRES. In all these patients, cerebral venous sinus thrombosis was ruled out by MR venography. During the follow-up period, there was resolution in the hematoma volume and all the patients were asymptomatic clinically. Admission blood pressure was recorded to be higher among individuals with hemorrhage compared to patients without hemorrhage (179.20/106.80 mm Hg versus 173.09/99.18 mm Hg, although this difference was statistically insignificant (P = 0.6) [Figures 1 and 2].

**Diffusion restriction in posterior reversible encephalopathy syndrome (n = 20)**
Six (30%) of patients had restricted diffusion on MR imaging. The sites included occipital and parietal regions (n = 6), cerebellum (n = 3), temporal/brain stem/basal ganglia (n = 1 each) [Figure 1].

**Contrast enhancement (n = 16)**
Four (25%) individuals had evidence of contrast enhancement. Four individuals did not undergo gadolinium enhanced evaluation primarily due to deranged renal function tests. The sites of contrast enhancement included parietal regions (n = 3) followed by frontal (n = 2) and temporal (n = 1) regions.

**Follow-up data**
Two (9.1%) patients succumbed to their illness. One of these had bilateral renal masses suggestive of renal malignancy. She (patient 6 in tables) presented with altered sensorium and tachypnea and was diagnosed to have PRES with aspiration pneumonia and sepsis. She was managed in our intensive care unit and succumbed on day 2 of the illness. Another patient (patient 7 in tables) developed HELLP syndrome with multi-organ dysfunction and acute kidney injury in setting of eclampsia. She was managed in intensive care unit but succumbed on day 5 of illness secondary to ventilator associated pneumonia with sepsis and septicemic shock. On detailed analysis, we could not find any clinical or imaging parameter which could predict final outcome in PRES at presentation, though there was a trend between need for mechanical ventilation (P = 0.065) and poor outcome.

![Figure 1](image1.png)
*Figure 1: Diffusion restriction in a patient with posterior reversible encephalopathy syndrome (a) with resolution of signal changes (b) at follow up*

![Figure 2](image2.png)
*Figure 2: Some uncommon imaging findings in posterior reversible encephalopathy syndrome. fluid-attenuated inversion recovery images showing hyperintense signal changes in bilateral cerebellar hemispheres (a and b, blue arrows) followed by resolution at follow up (c). T2 weighted (d) and susceptibility weighted imaging (e) showing right sided frontal cortical and subcortical hemorrhage with signal changes which resolved leaving an gliotic scar at follow up imaging (f). (g and h): T2 weighted images showing left insular and basal ganglionic signal changes (g) and extensive subcortical white matter changes (h)*
All the remaining patients were followed up for a minimum of 3 months both clinically and by MRI. MRS score at admission was 5 in 16 patients, 4 in 2 patients, and 3 in 4 patients. At 3 months follow-up, MRS was 0 in 19 patients and 1 in 1 patient. Thus, all the patients were functionally independent at follow-up. Follow-up MRI at 3 months revealed complete resolution of signal abnormalities in 16 (80%) and partial resolution of signal abnormalities in four (20%) patients. All four individuals with partial resolution had hemorrhages. All these four patients are doing well during follow-up period.

### Neuro-ophthalmological and other investigation findings

In the current study, all patients underwent ophthalmology evaluation at presentation and at follow-up. Fundus examination did not reveal disc edema in any patient. There were changes suggestive of hypertensive retinopathy in 4 (18.2%) patients. VEPs (Goggle) were done at presentation only in all five patients with visual disturbances. Both the patients without visual perception and one patient with visual disturbances had absent waveforms. At follow-up, flash VEPs were normal in all these patients. Bedside EEG was done in all patients with encephalopathy. However, it could be done

---

**Table 1: Clinical features of the patients in the study group**

| Age (years) | Sex | Encephalopathy | Seizures | Head-ache | Visual disturbance | Vomiting | Other | Primary disease | Possible etiology for PRES |
|-------------|-----|----------------|----------|-----------|-------------------|----------|-------|----------------|--------------------------|
| 45          | Female | + | + | - | - | - | - | Wegener’s granulomatosis, pauci-immune glomerulonephritis | HT |
| 34          | Female | - | - | + | - | - | - | Right hemiparesis, right UMN CN VII | Essential hypertension | HT |
| 60          | Male | - | - | + | - | + | Vertigo | Chronic kidney disease stage 5, Hypertension | HT |
| 68          | Female | + | + | - | - | - | - | Essential hypertension | HT |
| 27          | Female | - | - | + | + | - | - | Renal lymphoma, chronic kidney disease Stage 5 | HT |
| 31          | Female | + | + | + | - | - | - | Antepartum eclampsia, HELLP syndrome | HT |
| 28          | Female | + | + | + | - | - | - | Chronic kidney disease stage 5 | HT |
| 15          | Male | + | + | + | + | - | HT retinopathy | Viral hepatitis, acute kidney injury | HT |
| 16          | Female | + | + | - | - | - | - | DRES syndrome (dapsone induced), ARDS | Drug induced |
| 32          | Female | + | + | - | - | - | - | Disseminated tuberculosis, Aspergillosis | Drug induced |
| 23          | Female | + | + | + | + | - | - | Antepartum eclampsia | HT |
| 25          | Female | + | + | + | - | - | - | Antepartum eclampsia | HT |
| 31          | Male | + | - | + | - | - | - | Postpartum eclampsia | HT |
| 25          | Male | - | - | + | + | + | - | Essential hypertension | HT |
| 31          | Female | + | - | - | - | - | - | Postpartum eclampsia | HT |
| 30          | Male | + | + | + | - | - | - | Organophosphate poisoning, acute kidney injury | HT |
| 22          | Female | + | + | + | - | - | - | HT retinopathy | Lupus nephritis class IV | HT |
| 20          | Female | + | + | - | - | - | - | Eclampsia | HT |
| 35          | Female | - | - | + | - | - | - | Eclampsia | HT |
| 25          | Female | + | + | + | - | - | - | Essential hypertension | HT |
| 30          | Female | + | - | - | - | - | - | Eclampsia | HT |

CN=Cranial nerve, +=Present, -=Absent, HT=Hypertensive, PRES=Posterior reversible encephalopathy syndrome, ARDS=Adult respiratory distress syndrome, UMN=Upper motor neuron, HELLP=Hemolysis, elevated liver enzymes and low platelet counts, DRES=Drug rash with eosinophilia and systemic symptoms.
in only seven patients during acute phase in whom it revealed diffuse slowing (theta-4; delta-3). Multifocal spikes were seen in three patients. None of the patients had evidence of electrical status. Follow-up EEG done at 3 months before tapering of antiepileptic drugs was normal in all (n = 20) patients. CSF examination done in three patients (number 9, 13, and 18) did not reveal any biochemical abnormality.

**Etiology of posterior reversible encephalopathy syndrome (n = 22)**

In the current study, eight (36.4%) patients had eclampsia, five (22.7%) had chronic kidney disease, five (22.7%) had essential hypertension and two each (9.1%) had immune mediated disorders and drug-induced PRES (one-dapsone; one-probably secondary to anti-tubercular/antifungal drugs).

**Discussion**

Although PRES has been described approximately 20 years back, our knowledge about this entity continues to be plagued by lack of well conducted prospective studies with good follow-up. In the current study, we prospectively followed 22 patients of PRES with complete clinical, ophthalmological and MRI data both at presentation and at 3 month follow-up to delineate its clinico-radiological profile and prognosis in a comprehensive manner.

**Demographic profile and clinical features**

The age and sex distribution in the present study was similar to that reported in several other studies.\[^{1,8,12}\] The main reason for female preponderance in current series is probably related to the fact that eclampsia accounted for 36.4% of all cases.

In the current series, the most common cause of PRES was eclampsia (36.4%) followed by hypertension and chronic kidney disease (22.7% each). Our findings are in direct agreement with three studies\[^{12-14}\] and in contrast to three studies who reported hypertension\[^{15}\] and drugs\[^{1,16}\] as the most common causes for PRES. The difference in etiologies in different series is likely related to differences in patient profile of various centers.

Regarding clinical features, though frequency of most of symptoms was similar to that reported previously,\[^{1,8}\] visual symptoms were reported less commonly in our series despite the fact that all patients underwent detailed evaluation by a trained neuro-ophthalmologist. The reason for this discrepancy...
is not clear. One reason for this may be that many of our patients were in encephalopathy at time of initial evaluation and thus they did not report visual disturbances.

**Neuroimaging findings**

The frequency of involvement of commonest brain regions (parietal and occipital) [Figure 3] in current series was similar to those described previously.[1,5,17] The involvement of atypical sites in present series was in accordance with several previously described studies.[12,16,18] In addition to involvement of atypical sites, we also noted presence of hemorrhages, diffusion restriction and contrast enhancement on MRI, features which are considered atypical for PRES. Knowledge of atypical radiological presentations of PRES will help primary care physicians as well as neurologists in more accurate diagnosis and better management of PRES. The comparison of atypical neuroradiological findings in different series is shown in table three.

**Outcome in posterior reversible encephalopathy syndrome**

Mortality is uncommon in PRES. Our study reports a mortality rate of 9.09%. Two individuals succumbed to death on day 2 and day 5 of hospitalization, respectively. Hinchey et al.[1] did not report mortality in his study group. Highest mortality was noted by Lee et al.,[15] who reported mortality rate of 15.1%. Both our patients who died had serious underlying multisystem disorders. Among the remaining 20 patients who survived, all were functionally independent at 3 month follow-up with MRS score being 0 in 95%. Sufficient data were not available to compare this finding with those of other authors. Regarding radiological recovery, nearly 75% of patients in our series showed complete radiological recovery at 3 months follow up similar to previously reported series.[1,11,15,16,18] We used intravenous methylprednisolone empirically in two patients who had absence of perception of light on ophthalmological examination. Both these patients recovered during the hospital stay. Steroids are known to benefit vasogenic edema and we used steroids in both the patients after ruling out infections and with meticulous attention to control of blood pressure. However, it should be noted that steroid use may be associated with PRES and thus future well conducted prospective studies are needed before their routine use can be recommended in PRES. On detailed analysis, we could not find any clinical or imaging parameter which could predict final outcome at time of presentation. Our findings were in contrast to a meta-analysis done by Chen et al.,[20] who reported presence of brain hemorrhage to be associated with poor and toxemia to pregnancy to be associated with good outcome in PRES (pooled odds ratio being 4.93 [95% confidence interval [CI]: 3.94–6.17; \( P < 0.0001 \)) for hemorrhage and 0.24 [95% CI: 0.15–0.40; \( P < 0.0001 \)) for toxemia of pregnancy, respectively]. The main reason for this discrepancy is likely related to small sample size of our study and the fact that most of patients showed good outcome in our cohort.

**Conclusion**

The present study has given important insights into clinico-radiological profile of PRES. Atypical MRI presentations are common and there is a need to keep a strong index of suspicion for diagnosis of PRES in appropriate clinical settings. With a mortality of <10%, we reaffirm the fact that, a catastrophic presentation of PRES does not foster a sinister outcome. In the absence of severe systemic disease and multiorgan dysfunction, we noted the outcome of PRES to be excellent.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500.
2. Schwartz RB, Jones KM, Kalina P, Bajakian RL, Mantello MT, Garada B, et al. Hypertensive encephalopathy: Findings on CT, MR imaging, and SPECT imaging in 14 cases. AJR Am J Roentgenol 1992;159:379-83.
3. Schwartz RB, Bravo SM, Klufas RA, Hsu L, Barnes PD, Robson CD, et al. Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol 1995;165:627-31.
4. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol 2008;65:205-10.
Bansal, et al.: Posterior reversible encephalopathy

5. Burnett MM, Hess CP, Roberts JP, Bass NM, Douglas VC, Josephson SA, et al. Presentation of reversible posterior leukoencephalopathy syndrome in patients on calcineurin inhibitors. Clin Neurol Neurosurg 2010;112:886-91.

6. Kozak OS, Wijdicks EF, Manno EM, Miley JT, Rabinstein AA. Status epilepticus as initial manifestation of posterior reversible encephalopathy syndrome. Neurology 2007;69:894-7.

7. Servillo G, Striano P, Striano S, Tortora F, Boccella P, De Robertis E, et al. Posterior reversible encephalopathy syndrome (PRES) in critically ill obstetric patients. Intensive Care Med 2003;29:2323-6.

8. Rajoor UG, Seema BN. Clinico-radiological spectrum of posterior reversible encephalopathy syndrome: A study from teaching hospital in North Karnataka. Int J Sci Stud 2015;3:111-4.

9. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20.

10. Sulter G, Steen C, De Keyser J. Use of the Barthel index and modified rankin scale in acute stroke trials. Stroke 1999;30:1538-41.

11. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2007;28:1320-7.

12. Karuppannasamy D, Vikrant K, Raghuram A, Kumaar TM. Cortical visual loss in posterior reversible encephalopathy syndrome in late postpartum eclampsia: Case series. Indian J Ophthalmol 2014;62:635-8.

13. McKinney AM, Sarikaya B, Gustafson C, Truwit CL. Detection of microhemorrhage in posterior reversible encephalopathy syndrome using susceptibility-weighted imaging. AJNR Am J Neuroradiol 2012;33:896-903.

14. Patil VC, Agrwal V, Rajput A, Garg R, Kshirsagar K, Chaudhari V. Clinical profile and outcome of posterior reversible encephalopathy syndrome (PRES). Ann Trop Med Public Health 2015;8:105-12.

15. Lee SY, Dinesh SK, Thomas J. Hypertension-induced reversible posterior leukoencephalopathy syndrome causing obstructive hydrocephalus. J Clin Neurosci 2008;15:457-9.

16. McKinney AM, Short J, Truwit CL, McKinney ZJ, Kozak OS, SantaCruz KS, et al. Posterior reversible encephalopathy syndrome: Incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol 2007;189:904-12.

17. Schwartz RB, Mulkern RV, Gudbjartsson H, Jolesz F. Diffusion-weighted MR imaging in hypertensive encephalopathy: Clues to pathogenesis. AJNR Am J Neuroradiol 1998;19:859-62.

18. Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: Controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol 2008;29:1043-9.

19. Brady E, Parikh NS, Navi BB, Gupta A, Schweitzer AD. The imaging spectrum of posterior reversible encephalopathy syndrome: A pictorial review. Clin Imaging 2018;47:80-9.

20. Chen Z, Zhang G, Lerner A, Wang AH, Gao B, Liu J, et al. Risk factors for poor outcome in posterior reversible encephalopathy syndrome: Systematic review and meta-analysis. Quant Imaging Med Surg 2018;8:421-32.